Mkt Cap$2.22T-0.22%
24h Vol$60.80B
BTC Dom56.2%
ETH Dom9.0%
F&G17Extreme Fear
BTC$62,423.00-0.16% ETH$1,660.95+0.09% USDT$0.99870.00% BNB$575.54+0.36% USDC$0.9998+0.01% XRP$1.09-2.08% SOL$68.95-0.35% TRX$0.3309+0.49% FIGR_HELOC$1.03-0.15% HYPE$61.92-1.53% DOGE$0.0783-1.44% USDS$0.9995-0.01% RAIN$0.016+1.42% LEO$9.54+0.12% ZEC$412.09-2.99% XLM$0.1902-1.48% BTC$62,423.00-0.16% ETH$1,660.95+0.09% USDT$0.99870.00% BNB$575.54+0.36% USDC$0.9998+0.01% XRP$1.09-2.08% SOL$68.95-0.35% TRX$0.3309+0.49% FIGR_HELOC$1.03-0.15% HYPE$61.92-1.53% DOGE$0.0783-1.44% USDS$0.9995-0.01% RAIN$0.016+1.42% LEO$9.54+0.12% ZEC$412.09-2.99% XLM$0.1902-1.48%
News

cancer trial

Total Stories
2
Section
cancer trial
Why Is Relmada Therapeutics (RLMD) Stock Up Today? NDV-01 Trial Update and $160M PIPE Deal
Market Analysis

Why Is RLMD Stock Surging Premarket? NDV-01 Trial Update and $160M PIPE Deal

Relmada Therapeutics stock surged after reporting positive Phase 2 trial results for NDV-01 and announcing a $160 million PIPE financing.

Tim FriesMar 9, 20264 min read